HISTORY
- 2021
-
- 11
- MG-PE3 PCT application
- 09
- MEPS-TBC, Manufactured & Released
- 08
- Series A (Bridge) – Korea Investment Partners Co., Ltd / SBI Investment Korea Co., Ltd. / KNOTUS Co., Ltd. / Tiumbio Co., Ltd
- 04
- MG-PE3 patent granted in Republic of Korea
- 03
- Started CRO evaluation of MG-PE3, new drug candidate for Alzheimer's disease - 1st Drug efficacy
- 02
- Kicked off MEPS-BBB research service using new drug candidates with pharmaceutical companies
- 01
- Expansion & relocation of the office, R&D center, and production facility (Hanyang Tower, 12, Beobwon-ro-11-gil, Songpa-gu, Seoul, Rep. of Korea)
- 2020
-
- 12
- Finished PK/PD CRO evaluation of MG-PE3, new drug candidate for Alzheimer's disease
- 10
- Venture Business Certification
- 08
- MEPS-TBC patent application (KR/US/PCT) & design application (KR/US/EU) MG-PE3 patent application (KR)
- 08
- Series A – Korea Investment Partners Co., Ltd / Tiumbio Co., Ltd
- 05
- Finalized technology transfer agreement with Georgia Tech. Registered Mepsgenlab as a subsidiary of Mepsgen
- 2019
-
- 09
- Founded Mepsgenlab Inc. (USA)
- 08
- Founded Mepsgen Co., Ltd. (Rep. of Korea)
Sitemap
